Related Experiment Video
Updated: Apr 17, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Structure-based lead optimization and biological evaluation of BAX direct activators as novel potential anticancer
Mariano Stornaiuolo1, Giuseppe La Regina, Sara Passacantilli
1Dipartimento di Farmacia, Università di Napoli "Federico II" , via D. Montesano 49, 80131 Naples, Italy.
Abstract:
The first direct activator of BAX, a pro-apoptotic member of the BCL-2 family, has been recently identified. Herein, a structure-based lead optimization turned out into a small series of analogues, where 8 is the most potent compound published so far. 8 was used as pharmacological tool to ascertain, for the first time, the anticancer potential of BAX direct activators and the obtained results would suggest that BAX direct activators are potential future anticancer drugs rather than venoms.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
Drug Discovery: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...

